（一）募集资金使用情况和存储情况 截至 2026 年 2 月 28 日，公司上述发行股份的募集资金使用情况具体如下： 单位：元 证券代码：920166 证券简称：海圣医疗 公告编号：2026-024 浙江海圣医疗器械股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、募集资金基本情况 2026 年 2 月 12 日，浙江海圣医疗器械股份有限公司发行普通股 11,294,118 股，发行方式为采用战略投资者定向配售和网上向开通北交所交易权限的合格投 资者定价发行相结合，发行价格为 12.64 元/股，募集资金总额为 142,757,651.52 元，实际募集资金净额为 113,438,208.84 元，到账时间为 2026 年 2 月 6 日。 二、募集资金使用情况 | 序号 | 募集资金用 | 实施主 | 募集资金计划 投资总额（调整 | 累计投入 募集资金 | 投入进度（%） （3）=（2）/ | | --- | --- | --- | --- | ...

证券代码：920166 证券简称：海圣医疗 公告编号：2026-023 浙江海圣医疗器械股份有限公司 关于使用募集资金置换预先已投入募投项目 及已支付发行费用的自筹资金的公告 二、使用募集资金置换预先已投入募集资金投资项目及已支付发行费用的 自筹资金情况 （一）以自筹资金预先支付发行费用情况 公司本次募集资金各项发行费用合计人民币 2,931.94 万元（不含增值税）， 截至 2026 年 2 月 28 日，公司已使用自筹资金支付发行费用金额为人民币 549.22 万元（不含增值税），本次拟用募集资金置换预先已支付发行费用金额人民币 549.22 万元（不含增值税）。 | 序 | 项目名称 | 发行费用（不含 | 自筹资金预先支付发行费 | 拟置换金额（不 | | --- | --- | --- | --- | --- | | 号 | | 税）（万元） | 用（不含税）（万元） | 含税）（万元） | | 1 | 保荐费用 | 500.00 | 180.00 | 180.00 | | 2 | 承销费用 | 900.00 | - | - | | 3 | 审计及验资费用 | 855.47 | 210.00 | 2 ...

浙江海圣医疗器械股份有限公司 关于召开 2026 年第二次临时股东会通知公告（提供网络投票） 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：920166 证券简称：海圣医疗 公告编号：2026-026 一、会议召开基本情况 （一）股东会届次 本次会议为 2026 年第二次临时股东会。 （二）召集人 本次股东会的会议召集、召开、议案审议程序等方面符合有关法律、行政法 规、部门规章、规范性文件和《公司章程》的规定。 （四）会议召开方式 本次会议采用现场投票和网络投票相结合方式召开。 本次股东会的召集人为董事会。 根据《公司法》和《公司章程》的有关规定，公司董事会于 2026 年 3 月 12 日召开第二届董事会第十五次会议，审议通过了《关于提请召开公司 2026 年第 二次临时股东会的议案》，表决结果为同意 9 票，反对 0 票，弃权 0 票。 （三）会议召开的合法合规性 公司同一股东只能选择现场投票、网络投票中的一种方式，同一表决权出 现重复表决的，以第一次投票结果为准。 （五）会议召开日期和 ...

证券代码：920166 证券简称：海圣医疗 公告编号：2026-020 浙江海圣医疗器械股份有限公司 第二届董事会第十五次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2026 年 3 月 12 日 2.会议召开地点：公司一楼 2 号会议室 1.议案内容： 3.会议召开方式：现场会议 4.发出董事会会议通知的时间和方式：2026 年 3 月 6 日以书面、通讯方式发 出 5.会议主持人：董事长黄海生 6.会议列席人员：全体高管 7.召开情况合法合规的说明： 本次会议的召集、召开程序，出席会议人员资格及召集人资格、会议的表决 程序均符合《中华人民共和国公司法》、《公司章程》及有关法律、法规和规定， 所作决议合法有效。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于变更公司注册资本、公司类型及修订<公司章程>的议案》 鉴于公司于 2026 年 2 月 12 日完成向 ...

Market Overview - As of February 28, 2026, the number of listed companies on the Beijing Stock Exchange (BSE) reached 295, with a total market capitalization of 942.59 billion, and an average market value of 3.195 billion per company. The proportion of national-level specialized and innovative enterprises is approximately 61.02%, while high-tech enterprises account for 91.19% [6][8]. Index Performance - The BSE 50 Index and the Specialized and Innovative Index closed at 1537.13 and 2581.02 points respectively by the end of February 2026. The BSE 50 Index experienced a monthly fluctuation of 0.36%, while the Specialized and Innovative Index had a fluctuation of 0.39% [2][12]. - The PE (TTM, excluding negative values) for the BSE 50 Index was 48.65 times, while the Specialized and Innovative Index had the lowest PE (TTM, excluding negative values) among similar indices at 69.79 times [23][27]. Industry Performance - In February 2026, only the power equipment industry (2.97%) and the computer industry (2.08%) showed positive average fluctuations, while other industries had negative average fluctuations. Year-to-date, the power equipment and computer industries had impressive average fluctuations of 16.06% and 7.35% respectively, while the automotive industry had the lowest at -5.87% [39][44]. - The PE (TTM, excluding negative values) for the computer and electronics industries was notably high at 149.12 times and 73.42 times respectively, while other industries ranged from 32.79 times to 46.55 times [44]. Liquidity Situation - The trading volume for the BSE 50 Index fluctuated between 16.379 billion and 22.508 billion, while the Specialized and Innovative Index ranged from 4.983 billion to 6.477 billion. The turnover rates for the BSE 50 Index and the Specialized and Innovative Index were maintained at 1.59% to 2.84% and 2.40% to 2.97% respectively [31][33]. Company Announcements and Regulatory Dynamics - The BSE 50 sample stocks underwent periodic adjustments, with three stocks including Jikang Technology being added, while three stocks including Aweit were removed. Several key companies reported their 2025 performance forecasts, with Bianxing Technology showing a revenue and net profit growth of 69.56% and 80.91% year-on-year, respectively [60][62].

Financing & Review - In February 2026, the Beijing Stock Exchange (BSE) issued 6 new stocks, raising a total of 1.635 billion yuan; the cumulative amount raised in January-February 2026 reached 3.414 billion yuan[5] - The average review cycle for companies was 251 days, with 6 companies passing the review and 2 terminating their applications[5] Subscription & Issuance - The median first-day price increase for the 3 new stocks listed in February was +142.31%, with individual increases of +202.96%, +142.31%, and +82.12% for Ai De Technology, Hai Sheng Medical, and Tong Bao Optoelectronics respectively[3] - The cumulative subscription yield for new stocks in January-February 2026 was +0.53%, while the total yield for 2025 was +3.31%[3] New Stock Subscription Yield & Rate Predictions - The expected total number of new stock issuances for 2026 has been raised to 50, with a total fundraising target of 14.375 billion yuan[5] - The median first-day increase for directly priced new stocks is projected at 250%, with various scenarios considered[5] Investment Analysis - The BSE is accelerating new stock issuance, with 11 new stocks issued in January-February 2026, nearing half of the total issuance for the previous year[5] - The report highlights a significant reduction in individual stock returns due to increased initial valuations, with the average price-earnings ratio for newly issued stocks at 14.99 times[5] Risk Factors - Potential risks include slower-than-expected issuance rates, lower-than-expected stock price increases, changes in the BSE's issuance system, and rapid growth in new stock subscription accounts[5]

证券代码：920166 证券简称：海圣医疗 公告编号：2026-019 二、募集资金监管协议的签署情况 浙江海圣医疗器械股份有限公司 关于签署募集资金三方监管协议的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、募集资金基本情况 浙江海圣医疗器械股份有限公司（以下简称"公司"）向不特定合格投资者 公开发行股票并在北京证券交易所上市申请于 2025 年 11 月 7 日经北京证券交易 所上市委员会审核同意，并于 2025 年 12 月 31 日获得中国证券监督管理委员会 （以下简称"中国证监会"）出具的《关于同意浙江海圣医疗器械股份有限公司 向不特定合格投资者公开发行股票注册的批复》（证监许可〔2025〕3028 号）， 公司股票于 2026 年 2 月 12 日在北京证券交易所上市。 公司本次向不特定合格投资者公开发行普通股 11,294,118 股，每股面值为 人民币 1.00 元，每股发行价格为 12.64 元，募集资金总额为人民币 142,757,65 1.52 元，扣除发行费用人民币（ ...

Group 1 - The average first-day increase for new stocks in February 2026 was 140%, indicating a slight cooling in market enthusiasm compared to 2025, where the average was 368% [2][24][28] - In February 2026, three companies were listed, raising a total of 7 billion yuan, continuing a rapid IPO pace [3][19][23] - The average revenue for newly listed companies in the first two months of 2026 was 8.1 million yuan, with an average net profit of 1.0 million yuan, reflecting an improvement in company quality compared to previous years [41][42][61] Group 2 - The average online subscription funds in February 2026 reached 8.039 billion yuan, maintaining high investor interest despite a slight decrease from previous months [31][29] - The average expected return for top-tier subscriptions in February 2026 was 11,000 yuan, with a total expected return of 78,000 yuan for the year to date [37][40] - The average subscription limit for new stocks in February 2026 was 1.01 million yuan, indicating a trend towards higher subscription capacities [32][36] Group 3 - In February 2026, five companies passed the IPO review, covering high-end manufacturing and intelligent equipment sectors, with several expected to raise over 400 million yuan [52][49] - As of the end of February 2026, 200 companies were preparing for IPOs, with an average review cycle of 386 days, showing a slight improvement in the speed of the IPO process [57][53] - The new three-board market saw 18 companies listed in February 2026, with an average revenue of 6.0 million yuan and a net profit of 0.6 million yuan, indicating a trend of higher quality listings [59][61]

Financial Performance - The company's operating revenue for the reporting period was CNY 345,286,102.13, representing a year-on-year increase of 13.68%[5] - The total profit for the period was CNY 97,744,458.73, reflecting a year-on-year growth of 20.15%[5] - Net profit attributable to shareholders was CNY 85,815,891.13, up 21.01% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 80,393,732.37, an increase of 18.16% year-on-year[5] - Basic earnings per share reached CNY 1.34, marking a 20.72% increase from the previous year[5] Assets and Equity - Total assets at the end of the reporting period amounted to CNY 596,510,511.68, a year-on-year increase of 20.25%[6] - Shareholders' equity attributable to the company was CNY 497,675,062.33, reflecting a growth of 21.07% year-on-year[6] Growth Drivers - The increase in profit was driven by market expansion and significant growth in product lines such as life information monitoring and airway management series[6] - The company experienced notable growth in regions including international markets, East China, North China, and Northeast China[6] - The increase in total assets and equity was attributed to ongoing construction projects and the expansion of production, sales, and procurement scales[6]

Core Insights - On February 27, 2026, Haiseng Medical (920166) was featured on the stock exchange's "Dragon and Tiger List" due to a turnover rate of 25.21%, with a trading volume of 5.991 million shares and a transaction value of 186 million yuan [1][2]. Trading Activity Summary - The top buying seat was Guojin Securities Co., Ltd. Shenzhen Branch, purchasing approximately 8.36 million yuan worth of shares [2]. - The top selling seat was Huatai Securities Co., Ltd. Taizhou Branch, selling approximately 5.19 million yuan worth of shares [2]. - Other notable buying activities included institutional investors and various securities firms, with significant amounts traded by multiple entities [2].